300+ Studies Manage Risks with CluePoints COVID-19 Support
CluePoints, a provider of Risk-Based Study Execution (RBx) and Data Quality Oversight Software for clinical trials, announced 183 studies across 22 sponsor and CRO organizations have taken advantage of CluePoints complimentary COVID-19 risk management package alongside comprehensive support for COVID-19 affected trials. Launched in April in the wake of COVID-19, the support package includes an online Risk Assessment and Control solution that can be leveraged for performing risk planning and mitigation activities addressing inherent risks during this crisis.
With sponsors and CROs facing a myriad of new recommendations and guidelines issued by the FDA, EMA, PMDA, MHRA and other local agencies due to coronavirus, the complimentary support package was offered to sponsors and CROs to keep up with the need to assess and control risk on new and ongoing studies, with documentation and audit trails even more important in this highly dynamic environment.
CluePoints has been commissioned to provide deeper analytical support to a further 135 studies.
Commenting on the support package, Patrick Hughes, Co-Founder and Chief Commercial Officer of CluePoints said, “We have also seen a significant increase in existing clients stepping up their data analysis to ensure early detection of issues needing urgent attention.”
In addition, CluePoints solutions have also been utilized in over 12 high-profile specific COVID-19 vaccine studies with leading pharma sponsors in conjunction with their top five CRO development partners.
Source: CluePoints
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
VERITAC-2 Trial Shows Vepdegestrant Significantly Improves Survival in ESR1-Mutant Breast Cancer
March 24th 2025Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant in patients with ESR1-mutant (ESR1m) advanced or metastatic breast cancer, but did not achieve statistical significance in the overall intent-to-treat population.
